Tagged with Access

Poland Denis Vujičić, managing director of MSD Poland, discusses his overriding mission to give Polish patients greater access to breakthrough therapies and highlights the affiliate’s extensive R&D capabilities that entail both domestic and global operations. Furthermore, he highlights the important steps that MSD is undertaking to strengthen its position as the…

Switzerland In an exclusive interview, Bruno Strigini, global CEO of Novartis Oncology, discusses the logic of the company’s separate oncology business unit, the significance of US FDA approval for the new CAR-T cell therapy, Kymriah, and the issues around pricing for this revolutionary treatment.   * Please note that this interview was…

Serbia Bojan Trkulja, managing director of INOVIA, Serbia’s innovative drug manufacturers association, underlines the importance of cooperation not only between his members but also between all the key stakeholders of the Serbian healthcare and life science industry, concluding that the time for investment in Serbia is now and that the country…

Brazil Pius Hornstein, MSc, PhD, country chair Sanofi Brazil and general manager Pharma, shares his positive outlook on the Brazilian pharma market over the next few years and details Sanofi’s strategy in Brazil; a ‘must-win’ market for the company. Unsatisfied with being just the top-ranked multinational pharma company in Brazil, he…

Brazil Laurena de Almeida Magnoni, regional director for Latin America at Besins Healthcare, a pharmaceutical company specialized in the development and worldwide diffusion of innovative drugs and food supplements for men’s and women’s health, provides insights into the impressive growth of the Brazilian operations over the past six years, her recipe…

Merck Belén Garijo, global CEO of Merck Healthcare, speaking this month at the FT Global Pharmaceutical and Biotechnology Conference, ‘Thriving Amid Uncertainty’, in London, underlined the significance of Merck’s new deal with NHS England for its innovative new multiple sclerosis (MS) treatment, Mavenclad and how this deal stands as a new…

Japan Dr. Tatsuya Kondo is chief executive of Japan’s regulatory authority, the Pharmaceuticals and Medical Devices Agency (PMDA). Since taking the role in 2008, Dr. Kondo, a qualified neurosurgeon with wide-ranging experience in R&D activities, has been responsible for all the operations of PMDA, including relief for adverse health effects of…

Brazil Josiel Florenzano, managing director of Lundbeck Brazil and South Cone, provides us with an overview of the main dynamics shaping the Brazilian CNS market as well as the opportunities he identifies to further increase awareness and improve market access in the mental health area. You took over the helm of…

Brazil Neide Kawabata, president of B Braun Brazil, shares B Braun’s long track record of success and commitment to Brazil, the innovations they continue to bring to the market, and the long-term vision and community support B Braun brings to its affiliates globally, as a sixth-generation family-owned company. Neide, could you…

Brazil Andrew Simpson, Scientific Director of Orygen, elaborates on the innovative collaboration model his company is taking part in to develop biotechnologies in Brazil, the importance of developing affordable treatments for Brazilians, and the company’s current research on immunostimulants. Before presenting the company, could you tell our readers what motivated you…

Poland Adam Czerw, country manager of LEO Pharma Poland, discusses the impressive growth of the affiliate, especially since the global 2016 purchase of Astellas’ dermatology portfolio, as well as the encouraging development of LEO’s first ever reimbursed product on the Polish market. Furthermore, he highlights the key steps to further reward…

India Dilip G Shah, secretary-general of the Indian Pharmaceutical Alliance (IPA) and member of the Expert Review Committee on Access to Medicine (ATM), discusses the association’s commitment to assisting the Indian government with policies that ensure access to affordable medicines for all as well as the requirements that every candidate needs…